Fintel reports that on January 3, 2025, Guggenheim upgraded their outlook for Surrozen (NasdaqCM:SRZN) from Neutral to Buy.

Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of ...

Shares of SRZN opened at $14.25 on Friday. Surrozen has a fifty-two week low of $6.00 and a fifty-two week high of $16.19. The firm has a 50-day simple moving average of $10.78 and a 200-day ...

As previously reported, Guggenheim upgraded Surrozen (SRZN) to Buy from Neutral with a $45 price target Recent Phase 1b data for SZN-043, the ...

Guggenheim analyst Yatin Suneja upgraded Surrozen (SRZN) to Buy from Neutral with a $45 price target Don't Miss Our New Year's Offers:Discover ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

As of December 23, 2024, the average one-year price target for Surrozen is $33.66/share. The forecasts range from a low of $33.33 to a high of $34.65. The average price target represents an ...